Abstract: A battery pack mounting structure of a vehicle includes: a frame side member of a chassis frame provided so that an upper end portion thereof is located at a position spaced downward by a predetermined reference downward distance from a step height set in consideration of ease of boarding of passengers; a battery case provided so that a battery accommodated in the battery case overlaps the frame side member in a horizontal direction thereof; a case side portion forming a side surface of the battery case, coupled to a lower side of the frame side member, and including a lower end portion aligned with a lowest ground height of the vehicle; and a case lower plate forming the battery case while supporting a lower side of the battery and disposed at a position spaced upwards from the lowest ground height.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

Abstract: Provided is a method for quantifying A? in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological A? accumulation occur. Through cut-off values of measured values measured by the method for quantifying A? according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of A? in the brain occurs, and it is possible to predict progression to AD.

Abstract: Provided is a method for quantifying A? in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological A? accumulation occur. Through cut-off values of measured values measured by the method for quantifying A? according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of A? in the brain occurs, and it is possible to predict progression to AD.